CN104244982A - 酪氨酸激酶抑制剂组合及其用途 - Google Patents

酪氨酸激酶抑制剂组合及其用途 Download PDF

Info

Publication number
CN104244982A
CN104244982A CN201380018928.6A CN201380018928A CN104244982A CN 104244982 A CN104244982 A CN 104244982A CN 201380018928 A CN201380018928 A CN 201380018928A CN 104244982 A CN104244982 A CN 104244982A
Authority
CN
China
Prior art keywords
tyrosine kinase
combination
met
fgfr
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018928.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·提耶德
A·博克勒
F·哈宾斯基
S·桑哈维
D·杰弗里
C·威尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104244982A publication Critical patent/CN104244982A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380018928.6A 2012-04-03 2013-04-01 酪氨酸激酶抑制剂组合及其用途 Pending CN104244982A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
US61/619,502 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
CN104244982A true CN104244982A (zh) 2014-12-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380018928.6A Pending CN104244982A (zh) 2012-04-03 2013-04-01 酪氨酸激酶抑制剂组合及其用途

Country Status (11)

Country Link
US (1) US20150051210A1 (https=)
EP (1) EP2833917A1 (https=)
JP (1) JP2015512447A (https=)
KR (1) KR20140146086A (https=)
CN (1) CN104244982A (https=)
AU (1) AU2013243737B2 (https=)
CA (1) CA2866321A1 (https=)
IN (1) IN2014DN07410A (https=)
MX (1) MX2014011987A (https=)
RU (1) RU2014143213A (https=)
WO (1) WO2013151913A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
ES2831416T3 (es) * 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
US12414945B2 (en) 2015-12-17 2025-09-16 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
AU2007309149C1 (en) 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
CA2683559C (en) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CA2720888A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2288383A1 (en) * 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEX KENTSIS ETAL: "Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition", 《BLOOD(ASH ANNUAL MEETING ABSTRACTS)》 *

Also Published As

Publication number Publication date
MX2014011987A (es) 2014-11-10
KR20140146086A (ko) 2014-12-24
JP2015512447A (ja) 2015-04-27
RU2014143213A (ru) 2016-05-27
IN2014DN07410A (https=) 2015-04-24
US20150051210A1 (en) 2015-02-19
AU2013243737A1 (en) 2014-09-25
EP2833917A1 (en) 2015-02-11
CA2866321A1 (en) 2013-10-10
WO2013151913A1 (en) 2013-10-10
AU2013243737B2 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
WO2023199180A1 (en) Therapeutic uses of a krasg12c inhibitor
KR20240024938A (ko) Kras g12c 저해제를 포함하는 약제학적 조합물 및 암의 치료를 위한 이의 용도
US20190134033A1 (en) Pharmaceutical combinations
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
TW202045171A (zh) 包含tno155和瑞博西尼之藥物組合
EP2834246B1 (en) Combination products with tyrosine kinase inhibitors and their use
Singh et al. Kinases inhibitors in lung cancer: From benchside to bedside
KR20140043314A (ko) 이중 오로라 키나제／ｍｅｋ 억제제를 사용한 항암 치료법
CN105209073A (zh) 包含B-Raf抑制剂和第二抑制剂的组合疗法
JP2024526135A (ja) Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法
TW201410247A (zh) 醫藥組合
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
JP2020529411A (ja) 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ
Zhang et al. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
AU2013243737B2 (en) Tyrosine kinase inhibitor combinations and their use
JP2023524789A (ja) Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ
US20250032458A1 (en) Treatment of cancer with an fgfr kinase inhibitor
ES2855075T3 (es) Combinación de ceritinib con un inhibidor de EGFR
CN121038792A (zh) 用met激酶抑制剂治疗癌症
Esdar et al. M4205 (IDRX-42) is a highly selective and potent inhibitor of relevant oncogenic driver and resistance variants of KIT in cancer
EP2608793B1 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2025111339A1 (en) Treatment of cancer with a parg inhibitor
Schellens et al. 564 POSTER First-in-human (FIH) study of PF-00299804 in advanced cancer patients: correlation between pharmacokinetics (PK) and pharmacodynamics (PD)
EA040191B1 (ru) Комбинированная терапия
TW201250004A (en) Anticancer therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141224